沙利度胺联合GP方案治疗晚期三阴性乳腺癌疗效观察

解华; 刘宏杰; 王玮; 解华; 刘宏杰; 王玮

doi:10.13898/j.cnki.issn.1000-2200.2017.07.012

[1]

BEIKI O,HALL P,EKBOM A,et al.Breast cancer incidence and case fatality among 4.7million women in relation to social and ethnic background:a population-based cohort study[J].Breast Cancer Res,2012,14(1):R5.

[2]

林志豪,金贞姬.沙利度胺治疗恶性肿瘤的研究进展[J].中国药业,2013,22(21):1.

[3]

ARMOIRY X,FAGNANI F,BENBOUBKER L,et al.Management of relapsed or refractory multiple myeloma in French hospitals and estimation of associated direct costs:a multi-centre retrospective cohort study[J]. J Clin Pharm Ther,2011,36(1):19.

[4]

孙燕,周际昌.临床肿瘤内科手册[M].4版,北京:人民卫生出版社,2004:44.

[5]

NAVRATIL J,FABIAN P,PALACOVA M,et al.Triple negative breast cancer[J].Klin Onkol,2015,28(6):405.

[6]

PRAT A,ADAMO B,CHEANG MC,et al.Molecular characterization of basal-like and non-basal-like triple-negative breast cancer[J].Oncologist,2013,18(2):123.

[7]

管小青,顾书成,郑向欣,等.TNBC的新辅助化疗:附31例报告[J].中国普通外科杂志,2014,23(11):1527.

[8]

WU J,LI S,JIA W,et al.Response and prognosis of taxanes and anthracyclines neoadjuvant chemotherapy in patients with triple-negative breast cancer[J].J Cancer Res Clin Oncol,2011,137(10):1505.

[9]

GHERSI D,WILLSON ML,CHAN MM,et al.Taxane-containing regimens for metastatic breast cancer[J].Cochrane Database Syst Rev,2015,6(10):3366.

[10]

WU K,YANG Q,LIU Y,et al.Meta-analysis on the association between pathologic complete response and triple-negative breast cancer after neoadjuvant chemotherapy[J].World J Surg Oncol,2014,12(95):1219.

[11]

谢娜,彭晔,王美芹,等.沙利度胺联合化学治疗肺癌临床研究进展[J].医学导报,2014,33(8):1059.

[12]

昝瑛,张寅斌,王西京,等.沙利度胺联合铂类方案治疗三阴性乳腺癌肝转移[J].现代肿瘤医学,2014,22(11):2626.

[13]

梁万霞,顾康生.沙利度胺联合DOF方案与单纯DOF方案一线治疗晚期胃癌的疗效观察[J].肿瘤防治研究,2015,42(3):278.

[14]

马守成,乔慧,杨天宁,等.沙利度胺联合GP方案治疗晚期乳腺癌的疗效分析[J].肿瘤学杂志,2016,22(6):519.

[15]

左彩莹.沙利度胺联合盐酸托烷司琼对转移性乳腺癌GP方案化疗所致的恶心、呕吐的疗效观察[J].肿瘤临床研究,2014,27(12):1491.